AZN News and Press, AstraZeneca PLC From 02/21/24

2024-02-21 11:51:31 ET Summary AstraZeneca PLC has announced a deal to acquire Gracell Biotechnologies Inc., a Chinese company focused on developing cell therapies for cancer and autoimmune diseases. The terms of the acquisition include a cash payment of $10 per Gracell ADR and a ...

2024-02-21 09:21:45 ET More on AstraZeneca AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca FY23 Earnings Review: It's OK To Buy Dip On Q4 Bottom Line Miss AstraZeneca PLC 2023 Q4 - Results - Earnings Call Presentation Daiichi Sankyo-AstraZe...

2024-02-20 17:40:54 ET Summary I have been tracking M&A stocks for almost 30 years and sharing insights with the Seeking Alpha community. The article focuses on M&A funds that own at least 3.5% of a stock involved in a merger or buyout. I highlight several stocks, incl...

2024-02-20 08:09:53 ET More on Gracell Biotechnologies With Its Sale To AstraZeneca, Gracell Blazes Exit Trail For Cash-Challenged Chinese Biotechs Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca to buy Gracell Biotechnologies for $1.2 ...

2024-02-19 07:36:17 ET Read the full article on Seeking Alpha For further details see: Daiichi Sankyo-AstraZeneca gets BLA approved for lung cancer therapy in the U.S.

2024-02-19 07:28:21 ET AstraZeneca ( NASDAQ: AZN ) said on Monday that results from LAURA Phase III trial showed that TAGRISSO demonstrated statistically significant, meaningful improvement in patients with unresectable, Stage III epidermal growth factor receptor-mutated...

Application based on results from the TROPION-Lung01 Phase III trial If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed antibody drug conjugate for patients with lung cancer AstraZeneca and Daiichi Sankyo’s Bi...

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) demonstrated a statistically significant and highl...

2024-02-19 02:06:33 ET The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's ( NASDAQ: AZN ) blockbuster cancer drug Tagrisso with chemotherapy for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non...

Application based on results from the TROPION-Lung01 phase 3 trial If approved, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan may be the first TROP2 directed antibody drug conjugate for patients with lung cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (L...